Plain-English translation of NCT05467748 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications — and pembrolizumab — for people with advanced lung cancer that has stopped responding to previous immunotherapy treatments. Researchers believe that may help 'wake up' cancer cells so they respond better to pembrolizumab, an immunotherapy drug. The study will first test the safety of this combination in a small group, then expand to test whether it actually helps patients.
While immunotherapy has helped many patients with advanced lung cancer, most people either don't respond to it or their cancer starts growing again after initial improvement. Researchers hope that this medication can work together with immunotherapy to help more patients benefit from treatment.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination for up to 2 years. In the first cycle, you'll take by mouth for 7 days before starting pembrolizumab as an intravenous infusion. After that, you'll continue taking daily and receive pembrolizumab infusions every 3 weeks. You'll have regular visits with the research team for blood tests, scans to measure your tumor, and to check for any side effects.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States